Urologia internationalis · 2025
Treatment Strategies in Oligo-Metastatic Prostate Cancer: A Nationwide Survey.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Borkowetz Angelika, Wullich Bernd, Saar Matthias, Schmidt-Hegemann Nina, Linxweiler Johannes
Аннотация
UNLABELLED: <p>Introduction: Metastasis-directed therapy (MDT) is a promising approach for recurrent or de novo oligo-metastatic castration-sensitive prostate cancer (omCSPC). The aim of this study was to evaluate the treatment approaches in omCSPC among German physicians.
METHODS: An anonymous online questionnaire was sent via <ext-link ext-link-type="uri" xlink:href="http://survio.com" xmlns:xlink="http://www.w3.org/1999/xlink">survio.com</ext-link> to the members of the German Societies of Urology and Radiooncology.
RESULTS: Participants (n = 166; 33% urologists, 66% radiooncologists) define omCSPC as ≤3 (31%) or ≤4 (58%) metastases. Multimodal therapy consisting of local therapy of the primary tumor, MDT, and androgen deprivation therapy (ADT) was favored. For local therapy, radiotherapy was the preferred approach (radiotherapy: 84%, prostatectomy: 16%). Overall, 77% and 76% considered MDT as (very) highly important in synchronous and metachronous omCSPC, respectively. In total, 80% would complement MDT with time-limited ADT. Compared to urologists, radiooncologists more often include cases with ≥3 metastases (p = 0.006) and see a higher importance of radiotherapy (p = 0.023), a lower importance of prostatectomy (p < 0.001) as well as a higher importance of MDT (in de novo p = 0.038, in metachronous p = 0.010).
CONCLUSION: MDT with time-limited ADT is a common treatment strategy in omCSPC. Especially in synchronous omCSPC, radiotherapy as local treatment for the primary is the preferred option rather than radical prostatectomy. </p>.
METHODS: An anonymous online questionnaire was sent via <ext-link ext-link-type="uri" xlink:href="http://survio.com" xmlns:xlink="http://www.w3.org/1999/xlink">survio.com</ext-link> to the members of the German Societies of Urology and Radiooncology.
RESULTS: Participants (n = 166; 33% urologists, 66% radiooncologists) define omCSPC as ≤3 (31%) or ≤4 (58%) metastases. Multimodal therapy consisting of local therapy of the primary tumor, MDT, and androgen deprivation therapy (ADT) was favored. For local therapy, radiotherapy was the preferred approach (radiotherapy: 84%, prostatectomy: 16%). Overall, 77% and 76% considered MDT as (very) highly important in synchronous and metachronous omCSPC, respectively. In total, 80% would complement MDT with time-limited ADT. Compared to urologists, radiooncologists more often include cases with ≥3 metastases (p = 0.006) and see a higher importance of radiotherapy (p = 0.023), a lower importance of prostatectomy (p < 0.001) as well as a higher importance of MDT (in de novo p = 0.038, in metachronous p = 0.010).
CONCLUSION: MDT with time-limited ADT is a common treatment strategy in omCSPC. Especially in synchronous omCSPC, radiotherapy as local treatment for the primary is the preferred option rather than radical prostatectomy. </p>.